Lhe conditions of administration of prolonged-release injectable suspensions VOCABRIA 600 mg (cabotegravir) and REKAMBYS 900 mg (rilpivirine) are changing.
Since November 6, 2024, for each of these drugs, only the first injection must be carried out in a hospital settinginstead of the first three previously [1].
Administration in a hospital setting is a precaution due to the risk postinjection reactions associated with these medications.
In addition, VOCABRIA and REKAMBYS must be injected by a healthcare professional, at two separate sites in the gluteus medius muscle (ventrogluteal site recommended) during the same visit. The order of the injections does not matter. The instructions relating to the preparation of these injections, intended for healthcare professionals and present in the box leaflet, must be followed carefully in order to reduce the risk of leakage. [2].
The conditions for prescribing and dispensing these medications do not change; a hospital prescription is mandatory (cf. our article of December 22, 2021).
As a reminder, cabotegravir, the active ingredient in VOCABRIA, is an integrase inhibitor (INI), and rilpivirine, the active ingredient in REKAMBYS, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). VOCABRIA and REKAMBIS are indicated in combination for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
Related News :